New Jersey Medical School Clinical Research Center is the only site in the state participating in a worldwide effort to enroll 3,800 HIV negative individuals in the first Phase 3 HIV vaccine efficacy trial conducted in more than a decade. To read the full article.
Recent Posts
- NJ ACTS Special Populations Virtual Seminar on 9/24 at 12pm – Register Now
- NJ ACTS CREST (R25) Funded
- NJ ACTS Workforce Development Internship Fall 2024 – Deadline Today
- Rutgers Health Researchers Find Disparities in Outcomes of Hospice Discharges.
- NJIT Researchers Close in on New Technology for Objectively Measuring Pain.
Categories
- Community (1,990)
- Covid (974)
- CTO Events (1)
- News (2,536)
- Pilots (20)